{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:39:03Z","timestamp":1794022743651,"version":"4.8.0"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2022,7,1]]},"DOI":"10.1001\/jamacardio.2022.0987","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T15:06:35Z","timestamp":1652886395000},"page":"760","source":"Crossref","is-referenced-by-count":336,"title":["Lipoprotein(a) and its Significance in Cardiovascular Disease"],"prefix":"10.1001","volume":"7","author":[{"given":"Freddy","family":"Duarte Lau","sequence":"first","affiliation":[{"name":"Department of Medicine, Yale New Haven Health, Bridgeport, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"hrv220001r1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2014the LP system.","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"11","key":"hrv220001r2","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States.","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"hrv220001r3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank.","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"hrv220001r4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"hrv220001r5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hrv220001r6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective mendelian randomization study and replication in a case-control cohort.","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"26","key":"hrv220001r7","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease.","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"hrv220001r8","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"23","key":"hrv220001r9","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status.","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"12","key":"hrv220001r10","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk.","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"hrv220001r11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a).","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"hrv220001r12","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3491764","article-title":"Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule.","volume":"2020","author":"Jawi","year":"2020","journal-title":"J Lipids"},{"issue":"1","key":"hrv220001r13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/0004563220968473","article-title":"Lp(a): when and how to measure it.","volume":"58","author":"Cegla","year":"2021","journal-title":"Ann Clin Biochem"},{"issue":"6","key":"hrv220001r14","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1515\/CCLM.2004.114","article-title":"First WHO\/IFCC international reference reagent for lipoprotein(a) for immunoassay--Lp(a) SRM 2B.","volume":"42","author":"Dati","year":"2004","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"hrv220001r15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies.","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hrv220001r16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/MOL.0000000000000753","article-title":"The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk.","volume":"32","author":"Reyes-Soffer","year":"2021","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"hrv220001r17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions.","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res"},{"issue":"4","key":"hrv220001r18","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis.","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"25","key":"hrv220001r19","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"hrv220001r20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. a scientific statement from the National Lipid Association.","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"1","key":"hrv220001r21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"hrv220001r22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): a call to action.","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"issue":"12","key":"hrv220001r23","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1210\/clinem\/dgaa674","article-title":"Lipid management in patients with endocrine disorders: an Endocrine Society Clinical Practice Guideline.","volume":"105","author":"Newman","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"hrv220001r24","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults.","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"2","key":"hrv220001r25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart study.","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"hrv220001r26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease.","volume":"63","author":"O\u2019Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"hrv220001r27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamacardio.2020.0728","article-title":"An exploratory analysis of proprotein convertase subtilisin\/kexin type 9 inhibition and aortic stenosis in the FOURIER trial.","volume":"5","author":"Bergmark","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"1","key":"hrv220001r28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke.","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hrv220001r29","first-page":"1","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease.","volume":"6","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"32","key":"hrv220001r30","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J"},{"issue":"9","key":"hrv220001r31","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck study.","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"hrv220001r32","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1161\/ATVBAHA.114.303462","article-title":"A common LPA null allele associates with lower lipoprotein(a) levels and coronary artery disease risk.","volume":"34","author":"Kyriakou","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"hrv220001r33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004494","article-title":"Distribution and medical impact of loss-of-function variants in the Finnish founder population.","volume":"10","author":"Lim","year":"2014","journal-title":"PLoS Genet"},{"issue":"1","key":"hrv220001r34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ng.2480","article-title":"Large-scale association analysis identifies new risk loci for coronary artery disease.","volume":"45","author":"Deloukas","year":"2013","journal-title":"Nat Genet"},{"issue":"4","key":"hrv220001r35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/HCO.0000000000000628","article-title":"The role of lipoprotein (a) in primary and secondary cardiovascular disease prevention: a systematic review of epidemiological studies.","volume":"34","author":"Kouvari","year":"2019","journal-title":"Curr Opin Cardiol"},{"issue":"2","key":"hrv220001r36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.amjcard.2014.10.015","article-title":"Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention.","volume":"115","author":"Konishi","year":"2015","journal-title":"Am J Cardiol"},{"issue":"9","key":"hrv220001r37","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/clc.2017.40.issue-9","article-title":"Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention.","volume":"40","author":"Feng","year":"2017","journal-title":"Clin Cardiol"},{"issue":"17","key":"hrv220001r38","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes).","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"hrv220001r39","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"hrv220001r40","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1194\/jlr.R051870","article-title":"Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis.","volume":"57","author":"Thanassoulis","year":"2016","journal-title":"J Lipid Res"},{"issue":"7","key":"hrv220001r41","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1210\/jc.2015-1096","article-title":"Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100,578 individuals from the general population.","volume":"100","author":"Langsted","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"hrv220001r42","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.pcad.2020.06.002","article-title":"Lipoprotein(a) and calcific aortic valve stenosis: a systematic review.","volume":"63","author":"Guddeti","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"hrv220001r43","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease.","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin Chem"},{"issue":"11[special]","key":"hrv220001r44","first-page":"8","article-title":"Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2020: part III.","volume":"68","author":"Puri","year":"2020","journal-title":"J Assoc Physicians India"},{"issue":"34","key":"hrv220001r45","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice.","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"hrv220001r46","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia.","volume":"73","author":"Ellis","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"hrv220001r47","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","article-title":"Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk.","volume":"79","author":"Trinder","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"hrv220001r48","first-page":"S19","article-title":"Lipoprotein(a) elevation: a new diagnostic code with relevance to service members and veterans.","volume":"36","author":"Engler","year":"2019","journal-title":"Fed Pract"},{"issue":"3","key":"hrv220001r49","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jacl.2017.04.006","article-title":"Trends in testing for lipoprotein(a) at an academic medical center over 13 years.","volume":"11","author":"Wilkinson","year":"2017","journal-title":"J Clin Lipidol"},{"key":"hrv220001r51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.003","article-title":"The dedicated \u201cLp(a) clinic\u201d: a concept whose time has arrived?","volume":"300","author":"Tsimikas","year":"2020","journal-title":"Atherosclerosis"},{"issue":"7","key":"hrv220001r52","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis.","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"1","key":"hrv220001r53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study.","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"hrv220001r54","doi-asserted-by":"publisher","DOI":"10.3390\/nu12072024","article-title":"Diet and Lp(a): does dietary change modify residual cardiovascular risk conferred by Lp(a)?","volume":"12","author":"Enkhmaa","year":"2020","journal-title":"Nutrients"},{"issue":"10155","key":"hrv220001r55","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"issue":"24","key":"hrv220001r56","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels.","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"hrv220001r57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome.","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hrv220001r58","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"issue":"10057","key":"hrv220001r59","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"hrv220001r60","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease.","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"hrv220001r61","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk.","volume":"79","author":"Mehta","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"hrv220001r62","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"hrv220001r63","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"hrv220001r64","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol.","volume":"78","author":"Schwartz","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"hrv220001r65","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes.","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hrv220001r66","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2337\/dc20-2842","article-title":"Relation of lipoprotein(a) levels to incident type 2 diabetes and modification by alirocumab treatment.","volume":"44","author":"Schwartz","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"hrv220001r67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/MED.0000000000000597","article-title":"Lipoprotein (a) and diabetes mellitus: causes and consequences.","volume":"28","author":"Ward","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"hrv220001r68","first-page":"413","article-title":"Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.","volume":"14","author":"Franchini","year":"2016","journal-title":"Blood Transfus"},{"issue":"3","key":"hrv220001r69","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.v34.3","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the Writing Committee of the American Society for Apheresis: the Eighth Special Issue.","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"issue":"5","key":"hrv220001r71","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jacc.2020.05.070","article-title":"Targeting RNA with antisense oligonucleotides and small interfering rna: JACC State-of-the-Art Review.","volume":"76","author":"Katzmann","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10002","key":"hrv220001r72","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"hrv220001r75","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels.","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"hrv220001r50","unstructured":"Saeed? A. Poll results: lipoprotein(a): what is your clinical practice? Accessed January 19, 2022. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2021\/08\/31\/18\/47\/poll-results-lipoprotein-a"},{"key":"hrv220001r70","unstructured":"Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes (MultiSELECT). ClinicalTrials.gov identifier: NCT02791802. Updated February 11, 2019. Accessed January 19, 2022. https:\/\/clinicaltrials.gov\/show\/NCT02791802"},{"key":"hrv220001r73","unstructured":"Assessing the Impact of Lipoprotein(a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON). ClinicalTrials.gov identifier: NCT04023552. Updated January 14, 2022. Accessed January 19, 2022. https:\/\/clinicaltrials.gov\/show\/NCT04023552"},{"key":"hrv220001r74","unstructured":"Olpasiran trials of cardiovascular events and lipoprotein(a) reduction - DOSE Finding study. ClinicalTrials.gov identifier: NCT04270760. Updated January 12, 2022. Accessed January 19, 2022. https:\/\/clinicaltrials.gov\/show\/NCT04270760"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2792280\/jamacardiology_duarte_lau_2022_rv_220001_1656698795.58704.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T10:46:18Z","timestamp":1727261178000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2792280"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":75,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2022.0987","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}